Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EsPhALL 2017/COG AALL1631 imatinib with two chemotherapy backbones in pediatric Ph+ ALL
NL-OMON52698Phase 3Recruiting
- Sponsor
- University of Milano-Bicocca
- Start
- Nov 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of imatinib in acute lymphoblastic leukemia (ALL), sponsored by University of Milano-Bicocca. Started Nov 2018; status: recruiting.
02
Drugs
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NL-OMON52698.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52698.